全文获取类型
收费全文 | 10537篇 |
免费 | 748篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 123篇 |
儿科学 | 262篇 |
妇产科学 | 171篇 |
基础医学 | 1426篇 |
口腔科学 | 347篇 |
临床医学 | 1429篇 |
内科学 | 1768篇 |
皮肤病学 | 85篇 |
神经病学 | 940篇 |
特种医学 | 354篇 |
外科学 | 1077篇 |
综合类 | 159篇 |
一般理论 | 8篇 |
预防医学 | 1256篇 |
眼科学 | 308篇 |
药学 | 775篇 |
中国医学 | 11篇 |
肿瘤学 | 810篇 |
出版年
2023年 | 34篇 |
2022年 | 34篇 |
2021年 | 91篇 |
2020年 | 99篇 |
2019年 | 170篇 |
2018年 | 156篇 |
2017年 | 137篇 |
2016年 | 170篇 |
2015年 | 207篇 |
2014年 | 255篇 |
2013年 | 452篇 |
2012年 | 649篇 |
2011年 | 760篇 |
2010年 | 379篇 |
2009年 | 376篇 |
2008年 | 664篇 |
2007年 | 739篇 |
2006年 | 763篇 |
2005年 | 752篇 |
2004年 | 678篇 |
2003年 | 642篇 |
2002年 | 671篇 |
2001年 | 150篇 |
2000年 | 109篇 |
1999年 | 122篇 |
1998年 | 116篇 |
1997年 | 96篇 |
1996年 | 71篇 |
1995年 | 91篇 |
1994年 | 75篇 |
1993年 | 82篇 |
1992年 | 88篇 |
1991年 | 112篇 |
1990年 | 86篇 |
1989年 | 94篇 |
1988年 | 75篇 |
1987年 | 67篇 |
1986年 | 66篇 |
1985年 | 72篇 |
1984年 | 67篇 |
1983年 | 77篇 |
1982年 | 75篇 |
1981年 | 78篇 |
1980年 | 64篇 |
1979年 | 54篇 |
1978年 | 33篇 |
1977年 | 45篇 |
1976年 | 45篇 |
1974年 | 39篇 |
1972年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
2.
3.
Phantana-angkool April Voci Amy E. Warren Yancey E. Livasy Chad A. Beasley Lakesha M. Robinson Myra M. Hadzikadic-Gusic Lejla Sarantou Terry Forster Meghan R. Sarma Deba White Richard L. 《Annals of surgical oncology》2019,26(12):3874-3882
Annals of Surgical Oncology - The role of sentinel lymph node biopsy (SLNB) when ductal carcinoma in situ with microinvasion (DCISM) is identified on core biopsy is unclear. Our aim was to assess... 相似文献
4.
5.
6.
Bo Yang Elizabeth L. Norton Terry Shih Linda Farhat Xiaoting Wu Whitney E. Hornsby Karen M. Kim Himanshu J. Patel G. Michael Deeb 《The Journal of thoracic and cardiovascular surgery》2019,157(4):1313-1321.e2
Objective
To compare perioperative and long-term outcomes in patients undergoing hemiarch and aggressive arch replacement for acute type A aortic dissection (ATAAD).Methods
From 1996 to 2017, we compared outcomes of hemiarch (n = 322) versus aggressive arch replacements (zones 2 and 3 arch replacement with implantation of 2-4 arch branches, n = 150) in ATAAD. Indications for aggressive arch were arch aneurysm >4 cm or intimal tear in the aortic arch that was not resectable by hemiarch replacement, or dissection of arch branches with malperfusion.Results
Patients in the aggressive arch group were significantly younger (mean age: 57 vs 61 years old) and had significantly longer hypothermic circulatory arrest, cardiopulmonary bypass, and aortic crossclamp times. There were no significant differences in perioperative outcomes between hemiarch and aggressive arch groups, including 30-day mortality (5.3% vs 7.3%, P = .38) and postoperative stroke rate (7% vs 7%, P = .96). Over 15 years, Kaplan–Meier survival was similar between hemiarch and aggressive arch groups (log-rank P = .55, 10-year survival 70% vs 72%). Given death as a competing factor, incidence rates of reoperation over 15 years (2.1% vs 2.0% per year, P = 1) and 10-year cumulative incidence of reoperation (14% vs 12%, P = .89) for arch and distal aorta pathology were similar between the 2 groups.Conclusions
Both hemiarch and aggressive arch replacement are appropriate approaches for select patients with ATAAD. Aggressive arch replacement should be considered for an arch aneurysm >4 cm or an intimal tear at the arch unable to be resected by hemiarch replacement, or dissection of the arch branches with malperfusion. 相似文献7.
8.
Abdominal Radiology - 相似文献
9.